Drug Trial Radar · NCT03844360
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Jan 31, 2016
Primary completion
Dec 31, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Wei ZhaoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- First posted
- Feb 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 day, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
Conditions
- Hematological Neoplasms
Interventions
BortezomibDrug
bortezomib was administered follow the doctor's advice.
EltrombopagDrug
eltrombopag was administered follow the doctor's advice.
ImatinibDrug
imatinib was administered follow the doctor's advice.
dasatinibDrug
dasatinib was administered follow the doctor's advice.
PegaspargaseDrug
pegaspargase was administered follow the doctor's advice.
Anti-Infective DrugsDrug
anti-infective drugs was administered follow the doctor's advice.
PEGylated Recombinant Human Granulocyte Colony-Stimulating FactorDrug
pegaspargase was administered follow the doctor's advice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- change of plasma concentration of bortezomibTime frame: at(0-0.5)h,(0.5-3)h,(24-48)h,(48-72)h hours after administration
- change of plasma concentration of eltrombopagTime frame: at (0.5-3)h,(3-6)h,(10-14)h,(20-24)h hours after oral administration
- change of plasma concentration of imatinibTime frame: at (0.5-2)h,(2-4)h,(10-14)h,(20-24)h hours after oral administration
- change of plasma concentration of dasatinibTime frame: at(0-0.5)h,(0.5-3)h,(10-14)h,(20-24)h hours after oral administration
- change of plasma concentration of pegaspargaseTime frame: at Day-1,Day(0-1),Day(3-5),Day(8-10),Day(13-14) after administration
- plasma concentration of anti-infective drugTime frame: through study completion, an average of 14 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Completed
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tanjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.